Canada Spends Logo

Explore our Budget 2026 analysis

Contribution: SIF Stream 2 - Growth

Resilience Biotechnologies Inc.

$93,848,000.00

816022

FY 2021-22 · 2021-05-17

Summary
This project will enhance Canada's biomanufacturing capabilities through expansion of aseptic fill-finish capacity, upgrades to critical manufacturing systems, and implementation of digital technologies at Resilience's Mississauga facility. The project’s work phase is scheduled to end on March 31, 2029.
Program
SIF Stream 2 - Growth
Location
Mississauga, Ontario, Canada
Recipient Type
For-profit organization
Business Number
720950070
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions

Amendments

Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.

AmendmentDateFiscal YearTotal
02020-11-202020-21$199,159,000.00
12021-05-172021-22$199,159,000.00
22021-05-172021-22$93,848,000.00

As published

Additional Information
The amendment provides for a 60 month extension. The contribution value was reduced to $93,848,000.
Additional Information (French)
La modification prévoit une prolongation de 60 mois. La valeur de la contribution a été réduite à 93 848 000 $.
Agreement End Date
2054-01-01
Agreement Number
816022
Agreement Start Date
2021-05-17
Agreement Title
816022
Agreement Title (French)
816022
Agreement Type
Contribution
Agreement Value
$93,848,000.00
Amendment Date
2026-05-14
Amendment Number
2
Description
This project will enhance Canada's biomanufacturing capabilities through expansion of aseptic fill-finish capacity, upgrades to critical manufacturing systems, and implementation of digital technologies at Resilience's Mississauga facility. The project’s work phase is scheduled to end on March 31, 2029.
Description (French)
Ce projet renforcera les capacités de biofabrication du Canada grâce à l'accroissement de la capacité de remplissage et de finition aseptiques, à la modernisation des systèmes de fabrication critiques et à la mise en oeuvre de technologies numériques sur le site de Resilience à Mississauga. La phase de travail du projet est prévue se terminer le 31 mars 2029.
Expected Results
The investment will allow the company to add mammalian cell culture (MCC), messenger ribonucleic acid (mRNA) and fill-finish capacity at a single site, including early development capabilities, in a digitally updated facility. It will increase manufacturing footprint and capabilities, improve operational efficiency, and strengthen Canada's ability to develop and manufacture innovative biologic medicines from clinical development through commercial production.
Expected Results (French)
Cet investissement permettra à l'entreprise d'ajouter, sur un site unique, des capacités de culture de cellules de mammifères (CCM), de production d'ARN messager (ARNm) et de remplissage-finition — incluant des capacités de développement précoce — au sein d'une installation modernisée grâce aux technologies numériques. Il permettra d'étendre l'empreinte et les capacités de fabrication, d'améliorer l'efficacité opérationnelle et de renforcer la capacité du Canada à développer et à fabriquer des médicaments biologiques innovants, depuis le stade du développement clinique jusqu'à la production commerciale.
Federal Riding
Mississauga--Streetsville
Federal Riding (French)
Mississauga--Streetsville
Federal Riding Number
35063
NAICS Code
325410
Organization Code
ic
Organization
Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
Program Name
SIF Stream 2 - Growth
Program Name (French)
FSI Volet 2 - Croissance
Program Purpose
Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services; Facilitate the growth and expansion of firms in Canada; Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
Program Purpose (French)
Favoriser les activités de R-D qui accéléreront le transfert de la technologie et la commercialisation de produits, de processus et de services novateurs ; faciliter la croissance et l'expansion des entreprises au Canada ; attirer et conserver des investissements de grande envergure au Canada ; et-faire progresser la recherche industrielle, le développement et la démonstration de technologies grâce à la collaboration entre les universitaires, les organisations à but non lucratif et le secteur privé.
Recipient Business Number
720950070
Recipient City
Mississauga
Recipient Country
CA
Recipient Legal Name
Resilience Biotechnologies Inc.
Recipient Operating Name
Resilience Biotechnologies Inc.
Recipient Postal Code
L5N8H9
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
033-2021-2022-Q1-816022
Resilience Biotechnologies Inc. - $93,848,000 Contrib… | Canada Spends